De Novo DNA Overview

  • Founded
  • 2012
  • Status
  • Private
  • Employees
  • 3
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $2M
Latest Deal Amount
  • Investors
  • 2

De Novo DNA General Information


Developer of a genetic system software designed to make predictions to improve the performance of genetic systems. The company's platform offers to combine predictive biophysical models with computational optimization algorithms to design synthetic DNA sequences with well-predicted functions and biotech researchers routinely use the software to custom-design their organisms, building and testing only the ones that will achieve their targeted capabilities, with applications in protein expression, protein engineering, biosensor engineering, metabolic engineering, and probiotic engineering, enabling biotech researchers to rapidly engineer organisms with desired capabilities without the trial-and-error of iterative experimentation.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Primary Office
  • 200 Innovation Boulevard
  • State College, PA 16803
  • United States
+1 (415) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

De Novo DNA Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Grant 01-Jan-2018 $2M Completed Profitable
1. Accelerator/Incubator Completed Startup
To view De Novo DNA’s complete valuation and funding history, request access »

De Novo DNA Comparisons

HQ Location
Total Raised
Post Valuation
Last Financing Details
Developer of a genetic system software designed to make predictions to improve the performance of genetic systems. The c
State College, PA
3 As of 2021


pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit
San Francisco, CA
00 As of 0000
000000000 - 00.00


o laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in volupta
000000000000000000000 00000000
San Francisco, CA
000 As of 0000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

De Novo DNA Competitors (2)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
TeselaGen Biotechnology Venture Capital-Backed San Francisco, CA 00 00.00 000000000 - 00.00
000000000 Venture Capital-Backed San Francisco, CA 000 00000 00000000000 00000
You’re viewing 2 of 2 competitors. Get the full list »

De Novo DNA Executive Team (1)

Name Title Board Seat Contact Info
Howard Salis Founder & Chief Executive Officer
To view De Novo DNA’s complete executive team members history, request access »

De Novo DNA Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

De Novo DNA Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Defense Advanced Research Projects Agency Government 000 0000 000000 0
Innovation Park at Penn State Accelerator/Incubator Minority 000 0000 000000 0
To view De Novo DNA’s complete investors history, request access »